Curasight enters into to partnership with Curium for uTrace in prostate cancer.
Curasight’s stock rise more than 20 percent today following the very important and positive announcement yesterday after the market close that the company has entered into an agreement with French based Curium to develop its uTRACE technology for prostate cancer until the product candidate gets approved in EU and US, while Curium will be responsible for manufacturing and commercialization. Curasight will receive up to USD 70 million in milestones based on development and commercialization progress and double-digit royalties on Curium sales in selected markets. Curasight will continue to have the right to develop and commercialize uTRACE for other indications outside prostate cancer area. With the agreement Curasight are finally able to confirm and validate the medical prospect and commercial potential of their uTRACE technology platform that investors have been waiting for. 👇
Read full announcement here: https://www.curasight.com/news/press-releases/2023/curasight-and-curium-announce-global-partnership-for-utrace-in-prostate-cancer/
Also, in our previously released One-Pager on Curasight it has been assumed that Curasight would be able to obtain external partnership deals as key to validate the uTRACE and later uTREAT technology platform.
Read the one-pager here: https://www.inderes.dk/research/curasight-one-pager-quick-overview-and-valuation
Disclaimer:
HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 11:40 AM 05-02-2023.
Curasight er en dansk biotekvirksomhed med fokus på at udvikle og forbedre opdagelsen og behandlingen af kræft på en mere skånsom og effektiv måde. På nuværende tidspunkt modtager patienter radioaktiv stråling i behandlingen mod kræft. Dette skader kræftcellerne, såvel som raske celler og væv i kroppen. Curasight teknologi er baseret på formålet om ikke at skade raske celler og væv. Virksomheden har to pipeline-produkter, der begge bruger radionuklid (nuklearmedicin) til at forbedre diagnosticering og behandling af forskellige kræfttyper; uTRACE bruger den såkaldte uPAR receptore som sidder på kræftceller, som en biomarkør til at diagnosticere kræften, samt dens udvikling. Selskabets andet product uTREAT, anvender uPAR som en receptor til at behandle kræften. Baseret på stærke fase 2-data, der allerede er indsamlet i 2022, forventes Curasight at forberede fase 3 til uTRACE senere i 2022 og 2023 for følgende fire kræfttyper: prostata, hjerne, neuroendokrine og hoved- og halskræft.
Read more on company page